- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01742611
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
June 8, 2015 updated by: Astellas Pharma Inc
ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
-
Hokkaido, Japan
-
Kansai, Japan
-
Kanto, Japan
-
Kyushu, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who completed study 1585-CL-0101 or new patients who meet following criteria
- Chronic kidney disease patients (eGFR < 60 mL/min/1.73 m2)
- Serum phosphorus measurement ≧4.6 mg/dl, <9.0 mg/dl
- Written informed consent
Exclusion Criteria:
- Patients with gastrointestinal surgery or enterectomy
- Patients with severe cardiac diseases
- Patients with severe constipation or diarrhea
- Patients with a history or complication of malignant tumors
- Patients with uncontrolled hypertension
- Patients treated with parathyroid intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP1585 group
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time-course changes in serum phosphorus levels
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Achievement rate of the target range of serum phosphorus level
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Time to achieve the target range of serum phosphorus level
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Time-course changes in serum calcium levels
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Time-course changes in serum intact PTH (parathyroid hormone) levels
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs
Time Frame: During 48 week treatment
|
During 48 week treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
December 4, 2012
First Submitted That Met QC Criteria
December 4, 2012
First Posted (Estimate)
December 5, 2012
Study Record Updates
Last Update Posted (Estimate)
June 9, 2015
Last Update Submitted That Met QC Criteria
June 8, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1585-CL-0102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)CompletedAcute Renal Failure | Chronic Renal InsufficiencyAustria
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
-
Novartis PharmaceuticalsCompletedChronic Renal InsufficiencyUnited States
-
Weill Medical College of Cornell UniversityGenentech, Inc.SuspendedChronic Renal InsufficiencyUnited States
-
University of Colorado, DenverNational Jewish HealthActive, not recruitingHeart Transplantation | Chronic Renal InsufficiencyUnited States
Clinical Trials on ASP1585
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1585United States
-
Astellas Pharma IncCompletedRenal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia | Renal DialysisJapan
-
Astellas Pharma IncCompletedA Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal DialysisRenal Insufficiency | Chronic Kidney Disease | Renal DialysisJapan
-
Astellas Pharma IncCompletedHealthy | Urine Phosphorus ExcretionJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedChronic Kidney DiseaseJapan
-
Astellas Pharma IncCompletedChronic Kidney Disease Patients on Hemodialysis With HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedA Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisRenal Insufficiency | Chronic Kidney Disease | HyperphosphatemiaJapan
-
Astellas Pharma IncCompletedChronic Renal Failure Patients With Hyperphosphataemia Receiving HemodialysisJapan
-
Astellas Pharma IncCompletedA Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on HemodialysisChronic Kidney Disease | HyperphosphatemiaJapan